C07K 14/57
Ifn-gamma
Official title: IFN-gamma
C07K14/57 (Ifn-gamma) appears on 337 US grants and 352 published applications in this corpus.
Search patents in C07K- Granted patents
- 337
- Published applications
- 352
- Assignees
- 254
- Inventors
- 830
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 4 | 0 |
| 1984 | 6 | 0 |
| 1985 | 1 | 0 |
| 1986 | 4 | 0 |
| 1987 | 10 | 0 |
| 1988 | 6 | 0 |
| 1989 | 11 | 0 |
| 1990 | 13 | 0 |
| 1991 | 4 | 0 |
| 1992 | 8 | 0 |
| 1993 | 3 | 0 |
| 1994 | 8 | 0 |
| 1995 | 2 | 0 |
| 1996 | 7 | 0 |
| 1997 | 10 | 0 |
| 1998 | 9 | 0 |
| 1999 | 13 | 0 |
| 2000 | 11 | 0 |
| 2001 | 10 | 2 |
| 2002 | 3 | 3 |
| 2003 | 9 | 14 |
| 2004 | 7 | 14 |
| 2005 | 5 | 19 |
| 2006 | 10 | 14 |
| 2007 | 13 | 9 |
| 2008 | 11 | 8 |
| 2009 | 9 | 7 |
| 2010 | 5 | 12 |
| 2011 | 9 | 12 |
| 2012 | 6 | 5 |
| 2013 | 8 | 6 |
| 2014 | 5 | 10 |
| 2015 | 6 | 9 |
| 2016 | 7 | 12 |
| 2017 | 5 | 10 |
| 2018 | 8 | 6 |
| 2019 | 5 | 17 |
| 2020 | 7 | 18 |
| 2021 | 6 | 26 |
| 2022 | 8 | 17 |
| 2023 | 8 | 24 |
| 2024 | 17 | 34 |
| 2025 | 11 | 29 |
| 2026 | 8 | 15 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Enhanced chimeric antigen receptor cells in hypoxic tumor microenvironment18 Aug 2026US 12,709,737 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Bicyclic peptide ligands specific for CD13719 May 2026US 12,630,588 B2BicycleTx Limited
- ASGPR-binding compounds for the degradation of extracellular proteins12 May 2026US 12,622,972 B2Avilar Therapeutics, Inc.
- Activatable cytokine polypeptides and methods of use thereof5 May 2026US 12,617,829 B2Werewolf Therapeutics, Inc.
- 5T4 single domain antibodies and therapeutic compositions thereof31 Mar 2026US 12,590,169 B2Inhibrx Biosciences, Inc.
- Recombinant expression vector for interferon-beta secretion and attenuated salmonella strain transformed by means of same8 Oct 2026US 2026/0306554 A1The Industry & Academic Cooperation in Chungnam National University (IAC)
- Engineered t cells3 Sep 2026US 2026/0258104 A1Intellia Therapeutics, Inc.
- Activatable cytokine polypeptides and methods of use thereof27 Aug 2026US 2026/0250345 A1Werewolf Therapeutics, Inc.
- Tcr molecules targeting kras mutation, cells and use of tcr molecules and cells20 Aug 2026US 2026/0240907 A1Beijing Dcty Biotech Co., Ltd.
- Methods for identifying disseminated cancer cells in breast cancer patients13 Aug 2026US 2026/0232728 A1H. Lee Moffitt Cancer Center and Research Institute, Inc.
Most cited
By later US patents
- Covalently linked polypeptide cell modulators269US 4,935,233 AG. D. Searle & Co. · 1990
- Consensus human leukocyte interferon188US 4,695,623 AAmgen Inc. · 1987
- Immunoglobulin chimeric monomer-dimer hybrids165US 7,348,004 B2Syntonix Pharmaceuticals, Inc. · 2008
- Mammalian peptide expression in plant cells161US 4,956,282 ACalgene, Inc. · 1990
- Derivatives of growth hormone and related proteins160US 6,608,183 B1Bolder Biotechnology, Inc. · 2003